56. Update from the ACTG
Session: Symposium: Research Highlights from the NIH AIDS Networks and Observational Cohorts
Thursday, October 20, 2011: 1:00 PM
Room: 210ABC


Daniel Kuritzkes, MD, FIDSA, Brigham and Women's Hospital, Cambridge, MA; Harvard Med Sch

Daniel R. Kuritzkes, MD received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious disease at Massachusetts General Hospital, and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is Professor of Medicine and Director of AIDS Research, Brigham & Women’s Hospital. He is also Principal Investigator of the Harvard AIDS Clinical Trials Unit. Dr. Kuritzkes has published more than 200 research articles, reviews and book chapters on antiretroviral therapy and on the problem of drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and is a member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy. He has served on numerous NIH committees and editorial boards, and previously served as Chair of the HIV Medicine Association Board of Directors. He currently serves as Principal Investigator and Chair of the AIDS Clinical Trials Group, and as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on antiretroviral therapy and drug resistance.



Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.